Protagonist Therapeutics, Inc. (PTGX) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $110.64: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: High short interest: 13%; Below-average business quality.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with two NDA-stage programs: Icotyde (oral IL-23R antagonist licensed to Johnson & Johnson, FDA NDA filed July 2025 for psoriasis) and rusfertide (injectable hepcidin mimetic partnered with Takeda, FDA NDA... Read more
Sell if holding. Engine safety override at $110.64: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: High short interest: 13%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Score 5.6/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Protagonist Therapeutics, Inc.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics had two programs at the NDA stage at fiscal year-end 2025: Icotyde, an oral IL-23R antagonist licensed to Johnson & Johnson, for which JNJ filed an FDA NDA in July 2025 for moderate-to-severe plaque psoriasis and submitted an application to the EMA in September 2025; and rusfertide, an injectable hepcidin mimetic, for which Takeda submitted an FDA NDA in December 2025 for polycythemia vera after rusfertide received Breakthrough Therapy designation in August 2025. The company held approximately $646.0 million in cash, cash equivalents, and marketable securities at December 31, 2025 and has never generated product sales revenue.
Protagonist Therapeutics earns revenue from collaboration milestone payments and, upon product approval, tiered royalties. Under the JNJ License and Collaboration Agreement entered in July 2017 and last amended in November 2024, JNJ assumed responsibility for all clinical development beyond Phase 1 and for commercialization; Protagonist has earned $337.5 million in milestone payments from JNJ to date and is eligible for up to $630 million in future milestones, plus tiered royalties of 6% to 10% on worldwide net Icotyde sales (weighted average 7.25% on the first $4.0 billion in annual net sales). Under the Takeda Collaboration Agreement signed in January 2024, Protagonist received a $300 million upfront payment and a $25 million milestone in September 2025 upon completion of the Phase 3 VERIFY trial, with up to $975 million in additional milestones available. The company expects to exercise its opt-out right from US profit-and-loss sharing in Q2 2026, converting to royalties of 14% to 29% on worldwide net rusfertide sales.
Show full overview
Both NDA-stage programs carry regulatory binary risk at the FDA. The agency could refuse applications, request additional data, or issue Complete Response Letters; in September 2021, rusfertide clinical studies were placed on a brief full clinical hold following a non-clinical finding of benign and malignant subcutaneous skin tumors in a rasH2 transgenic mouse model. JNJ has disclosed it expects to launch Icotyde in the United States in 2026, subject to regulatory approval, while Takeda expects to launch rusfertide in the second half of 2026, subject to approval. If either NDA fails, the royalty stream that constitutes the primary source of non-milestone income would not materialize on the anticipated timeline.
See also: Healthcare · Biotechnology
From Protagonist Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-17Recent Developments — Protagonist Therapeutics, Inc.
Latest news
- NEWS Why Did Protagonist Therapeutics Stock Soar Today? - MSN — MSN positive
- NEWS Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS Citizens raises Protagonist Therapeutics stock price target on platform validation - Investing.com — Investing.com positive
- NEWS Protagonist Therapeutics: Q1 Earnings Snapshot - KING5.com — KING5.com neutral
- NEWS Protagonist Therapeutics: Q1 Earnings Snapshot - wwltv.com — wwltv.com neutral
Generated 2026-06-17T08:41:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineIcotyde and rusfertide10-K Item 1A: 'Our future success is substantially dependent on our ability and the ability of our collaborators...such as Icotyde and rusfertide'
- HIGHcounterpartyJNJ10-K Item 1A: 'If JNJ does not elect to continue the development of or successfully commercialize Icotyde...our business and business prospects would be adversely affected'
- HIGHcounterpartyTakeda10-K Item 1A: 'Under the terms of the Takeda Collaboration Agreement, Takeda may terminate the agreement for convenience in its entirety or as to a major region'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $110.64: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: High short interest: 13%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Prior stop was $102.90. Score 5.6/10, moderate confidence.
Take-profit target: $111.39 (+0.7% upside). Prior stop was $102.90. Stop-loss: $102.90.
Concentration risk — Pipeline: Icotyde and rusfertide; Concentration risk — Counterparty: JNJ; Target reached (-6.7% upside).
Protagonist Therapeutics, Inc. trades at a P/E of N/A (forward -164.3). TrendMatrix value score: 4.0/10. Verdict: Sell.
20 analysts cover PTGX with a consensus score of 4.3/5. Average price target: $119.
What does Protagonist Therapeutics, Inc. do?Protagonist Therapeutics is a clinical-stage biopharmaceutical company with two NDA-stage programs: Icotyde (oral...
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with two NDA-stage programs: Icotyde (oral IL-23R antagonist licensed to Johnson & Johnson, FDA NDA filed July 2025 for psoriasis) and rusfertide (injectable hepcidin mimetic partnered with Takeda, FDA NDA filed December 2025 for polycythemia vera). Milestone and royalty payments from JNJ and Takeda are the sole revenue sources; the company held $646 million in cash at December 31, 2025.